Peptide-modified liposomes for selective targeting of bombesin receptors overexpressed by cancer cells: a potential theranostic agent

Accardo, Antonella; Salsano, Giuseppina; Morisco, Anna; Aurilio, Michela; Parisi, Antonio; Maione, Francesco; Cicala, Carla; Tesauro, Diego; Aloj, Luigi; Rosa, Giuseppe De; Morelli, Giancarlo

doi:10.2147/ijn.s29242

Cited by 26 publications

(16 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Antitumor activity of RGD-targeted liposomes is consistent with tumor microvessel destruction after injection of RGD-targeted paclitaxel-loaded liposomes reported by another group [178]. Functionalization of doxorubicin-loaded liposomes with a peptide targeted to bombesin receptors overexpressed in cancers improved therapeutic efficacy over untargeted liposomes [179]. α 5 β 1 is another integrin overexpressed in cancer in which the fibronectin-derived peptide antagonist ATN-161 showed antineoplastic and antimetastatic properties [180].…”

Section: Biological Targetssupporting

confidence: 69%

Recent Trends in Multifunctional Liposomal Nanocarriers for Enhanced Tumor Targeting

Perche

Torchilin

2013

Journal of Drug Delivery

195

144

View full text Add to dashboard Cite

Liposomes are delivery systems that have been used to formulate a vast variety of therapeutic and imaging agents for the past several decades. They have significant advantages over their free forms in terms of pharmacokinetics, sensitivity for cancer diagnosis and therapeutic efficacy. The multifactorial nature of cancer and the complex physiology of the tumor microenvironment require the development of multifunctional nanocarriers. Multifunctional liposomal nanocarriers should combine long blood circulation to improve pharmacokinetics of the loaded agent and selective distribution to the tumor lesion relative to healthy tissues, remote-controlled or tumor stimuli-sensitive extravasation from blood at the tumor's vicinity, internalization motifs to move from tumor bounds and/or tumor intercellular space to the cytoplasm of cancer cells for effective tumor cell killing. This review will focus on current strategies used for cancer detection and therapy using liposomes with special attention to combination therapies.

show abstract

Section: Biological Targetssupporting

confidence: 69%

Recent Trends in Multifunctional Liposomal Nanocarriers for Enhanced Tumor Targeting

Perche

Torchilin

2013

Journal of Drug Delivery

195

144

View full text Add to dashboard Cite

show abstract

“…BnR-agonists coupled to liposomes and 99m Tc showed high specificity/selectivity for imaging breast-cancer-cells in tumor-bearing nude-mice[97]. BnR-peptide-agonist ligands have been coupled to liposomes, which can, when loaded with doxorubicin or other cytotoxic-agents, demonstrate specific cytotoxicity for cancer-cells[98–102]. In a number of studies a liposome-doxorubicin-complex conjugated to a BnR-agonist showed greater tumoral cytotoxicity than free liposome-doxorubicin-complex[100,102].…”

Section: Imaging and Targeted-delivery Of Cytotoxic-agents To Neopmentioning

confidence: 99%

Bombesin related peptides/receptors and their promising therapeutic roles in cancer imaging, targeting and treatment

Moreno

Ramos-Álvarez

Moody

et al. 2016

Expert Opinion on Therapeutic Targets

102

View full text Add to dashboard Cite

Introduction Despite remarkable advances in tumor treatment, many patients still die from common tumors (breast, prostate, lung, CNS, colon, and pancreas), and thus, new approaches are needed. Many of these tumors synthesize bombesin (Bn)-related peptides and over-express their receptors (BnRs), hence functioning as autocrine-growth-factors. Recent studies support the conclusion that Bn-peptides/BnRs are well-positioned for numerous novel antitumor treatments, including interrupting autocrine-growth via the use of over-expressed receptors for imaging and targeting cytotoxic-compounds, either by direct-coupling or combined with nanoparticle-technology. Areas covered The unique ability of common neoplasms to synthesize, secrete, and show a growth/proliferative/differentiating response due to BnR over-expression, is reviewed, both in general and with regard to the most frequently investigated neoplasms (breast, prostate, lung, and CNS). Particular attention is paid to advances in the recent years. Also considered are the possible therapeutic approaches to the growth/differentiation effect of Bn-peptides, as well as the therapeutic implication of the frequent BnR over-expression for tumor-imaging and/or targeted-delivery. Expert opinion Given that Bn-related-peptides/BnRs are so frequently ectopically-expressed by common tumors, which are often malignant and become refractory to conventional treatments, therapeutic interventions using novel approaches to Bn-peptides and receptors are being explored. Of particular interest is the potential of reproducing BnRs in common tumors, such as the recent success of utilizing overexpression of somatostatin-receptors by neuroendocrine-tumors to provide the most sensitive imaging methods and targeted delivery of cytotoxic-compounds.

show abstract

“…In addition BnR agonists have been one of the main targeting agents coupled to various nanoparticle carriers to assess delivery [44,342] or for targeted delivery of various cytotoxic agents including chemotherapeutic agents [docataxel [157], doxorubicin [1,3]]; radiolabeled analogues [140]; or gold nanoparticles [45]. Similarly various BnR agonists have been coupled to liposomes or micelles for target delivery of various cytotoxic agents including chemotherapeutic agents [4], radiolabeled compounds [2] or various cytotoxic Au-coupled compounds [289]. …”

Section: Bnr Function In Disease and A Therapeutic Target (Table 3)mentioning

confidence: 99%

Insights into bombesin receptors and ligands: Highlighting recent advances

et al. 2015

View full text Add to dashboard Cite

This following article is written for Prof. Abba Kastin’s Festschrift, to add to the tribute to his important role in the advancement of the role of peptides in physiological, as well as pathophysiological processes. There have been many advances during the 35 years of his prominent role in the Peptide field, not only as editor of the journal Peptides, but also as a scientific investigator and editor of two volumes of the Handbook of Biological Active Peptides [146,147]. Similar to the advances with many different peptides, during this 35 year period, there have been much progress made in the understanding of the pharmacology, cell biology and the role of (Bombesin) Bn receptors and their ligands in various disease states, since the original isolation of bombesin from skin of the European frog Bombina bombina in 1970 [76]. This paper will briefly review some of these advances over the time period of Prof Kastin 35 years in the peptide field concentrating on the advances since 2007 when many of the results from earlier studies were summarized [128,129]. It is appropriate to do this because there have been 280 articles published in Peptides during this time on Bombesin-related peptides and it accounts for almost 5% of all publications. Furthermore, 22 Bn publications we have been involved in have been published in either Peptides [14,39,55,58,81,92,93,119,152,216,225,226,231,280,302,309,355,361,362] or in the Prof Kastin’s Handbook of Biological Active Peptides [137,138,331].

show abstract

Peptide-modified liposomes for selective targeting of bombesin receptors overexpressed by cancer cells: a potential theranostic agent

Cited by 26 publications

References 35 publications

Recent Trends in Multifunctional Liposomal Nanocarriers for Enhanced Tumor Targeting

Recent Trends in Multifunctional Liposomal Nanocarriers for Enhanced Tumor Targeting

Bombesin related peptides/receptors and their promising therapeutic roles in cancer imaging, targeting and treatment

Insights into bombesin receptors and ligands: Highlighting recent advances

Contact Info

Product

Resources

About